## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.9% in lower entry zone (4.0-10.0%), top 5% cross-sectional ranking. Short-term MRS_5 (1.2%) confirms momentum alignment. Strong momentum (+1.4% 5-day acceleration). Outperforming sector by 4.2%. Caution: declining volume (56% of avg), overbought RSI (80).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($96.25)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Nasdaq, Coinbase and S&P Global named Clear Street’s top picks for 2026**
- Source: Investing.com | 20251226T123319 | Bullish | Relevance: 100%
- Clear Street analysts have identified Nasdaq Inc. (NDAQ), Coinbase Global Inc. (COIN), and S&P Global Inc. (SPGI) as their top investment ideas for 2026, assigning Buy ratings and specific price targets. The selections are based on five key industry themes, including tokenization, regulatory technology demand due to AI fraud, AI-enabled shopping, recovering capital markets, and the expectation of lower interest rates. Nasdaq's consistent dividend growth, Coinbase's blockchain positioning, and S&P Global's multiple catalysts were highlighted as drivers for their respective potentials.

**2. ACJAGXX Stock Price and Chart — NASDAQ:ACJAGXX**
- Source: TradingView — Track All Markets | 20251226T150855 | Neutral | Relevance: 82%
- This page provides the stock price and chart for ACJAGXX, a NASDAQ-listed security under the name Bank of Montreal Point to Point Buffer Note. The market for ACJAGXX is currently closed, with no trades reported. The platform also offers related funds and various financial tools.

**3. Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV**
- Source: The Town Talk | 20251226T190942 | Neutral | Relevance: 65%
- RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, December 27, at 7 p.m. Eastern Time (ET). Processa Pharmaceuticals will discuss its Next Generation Cancer (NGC) platform and preclinical updates for its Phase 2 study of NGC-Cap, aimed at breast cancer treatment. 60 Degrees Pharmaceuticals will focus on ARAKODA® (tafenoquine), an FDA-approved antimalarial, and its potential expansion for babesiosis treatment.

**4. Form 424B2 JPMORGAN CHASE & CO**
- Source: StreetInsider | 20251224T040859 | Neutral | Relevance: 64%
- JPMorgan Chase Financial Company LLC is offering Callable Contingent Interest Notes linked to the Nasdaq-100® Technology Sector Index SM, the Russell 2000® Index, and the S&P 500® Index, due December 3, 2027. These notes are designed for investors seeking contingent interest payments based on the performance of the least performing index, with potential for early redemption. Investors face the risk of losing principal and may not receive interest payments if the indices fall below specified barriers.

**5. Swedbank AB Invests $8.65 Million in Astera Labs, Inc. $ALAB**
- Source: MarketBeat | 20251228T101005 | Neutral | Relevance: 64%
- Swedbank AB recently invested approximately $8.65 million in Astera Labs, acquiring 44,200 shares in the third quarter, signaling renewed institutional interest. Astera Labs exceeded Q3 expectations, reporting $0.49 EPS and $230.58 million in revenue, and provided optimistic Q4 guidance. Despite significant institutional ownership, insiders have sold a substantial number of shares recently, although they still retain a 12.5% stake in the company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-22 | Morgan Stanley | $111 | $110 | +1% |
| 2025-12-12 | Barclays | $114 | $109 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-22 | Morgan Stanley | main | Overweight |
| 2025-12-12 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($2.76M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Volume divergence: price rising (+1.4% MRS) on declining volume (56% of avg) suggests distribution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.52 elevated, pricing in significant growth expectations. Forward P/E 26.0x stretched relative to 11% growth. Quality metrics strong (margin 20%). Insider selling cluster ($2.8M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $57.0B |
| Beta | 1.02 |
| 52W Range | $64.84 - $99.42 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.52 |
| Forward P/E | 26.0 |
| Current P/E | 29.0 |
| YoY Growth | 11.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 4.5% to 5.9% (+1.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 95th percentile. MRS_5 at 1.2% confirms short-term momentum alignment. AM_20 at 6.9% shows strong absolute momentum above own 20MA. Outperforming sector by 4.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.67), confirming momentum. RSI overbought at 80, risk of mean reversion. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.88% (CS: 95) | Strong |
| RSI_14 | 79.8 | Overbought |
| MACD Histogram | 0.67 | Bullish |
| vs SMA20 | 1.068x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.147x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $99.35
- **Stop Loss:** $96.25 (3.1% risk)
- **Target:** $104.00 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 425
- **Position Value:** $42,223.75
- **Portfolio %:** 42.22%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*